Sox17-Expressing Reprogrammed Endothelial Cells for Stable Vascular Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating endothelial cells for vascular regeneration face challenges in purifying and expanding primary ECs, with reprogramming approaches often resulting in unstable or immature cells, and existing strategies fail to meet the requirements of stable expansion, engraftment, and functional integration of ECs into host vasculature.
Innovation Solution
The method involves expressing the transcription factor Sox17 in reprogramming-derived endothelial cells (rECs) to enhance their functionality and engraftability, using a combination of enforced expression of ETS family transcription factors and inhibition of the TGFβ signaling pathway, which allows for the stable conversion of non-vascular cells into functional ECs that can form vascular networks and integrate into existing vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If reprogramming approaches are used to generate endothelial cells, then the availability of transplantable ECs is improved, but the stability and maturity of the generated cells deteriorates
Solution Approach 1:
The patent changes the molecular parameters by introducing specific transcription factors (ETV2, FLI1, ERG) and modulating signaling pathways (inhibiting TGFβ, activating Wnt/β-catenin) to transform the cellular state from non-vascular to endothelial, achieving both quantity and quality of ECs simultaneously
Solution Approach 2:
The patent uses small molecule inhibitors (SB431542 for TGFβ, IWR-1 for Wnt) as intermediaries to precisely control signaling pathways during reprogramming, enabling stable and mature EC generation by mediating the interaction between external factors and cellular reprogramming processes
2Reliability
If primary ECs are purified and expanded for transplantation, then the functionality for vascular regeneration is improved, but the difficulty of purification and expansion increases
Solution Approach 1:
The patent creates a copy of endothelial cell function and identity by reprogramming non-vascular cells to express endothelial-specific transcription factors and signaling profiles, producing transplantable ECs that replicate the regenerative functionality of primary ECs without requiring their difficult purification and expansion
3Reliability
If transcription factors are enforced to convert non-vascular cells to ECs, then the engraftment capability is improved, but the complexity of the reprogramming process increases
Solution Approach 1:
The patent segments the reprogramming process into distinct molecular components: three key transcription factors (ETV2, FLI1, ERG) and two signaling pathways (TGFβ inhibition and Wnt activation), allowing systematic control and optimization of each element to achieve reliable engraftment while managing overall process complexity
Data Source
AI summary
This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from non-vascular cells that display improved functionality and engraftability. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed.